Pathalys Pharma: Funding, Investors & Team (Oct 2026)
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).
Pathalys Pharma has raised $105M across 1 funding round on record, the most recent a Series B of $105M announced in Aug 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pathalys Pharma Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Pathalys Pharma Funding Rounds
Pathalys Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Pathalys Pharma Funding Compared to Other Biotechnology Startups
Pathalys Pharma's latest round of $105M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pathalys Pharma in Biotechnology and Raleigh
Companies Similar to Pathalys Pharma
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Pathalys Pharma Funding FAQs
What does Pathalys Pharma do?
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).
How much funding has Pathalys Pharma raised?
Pathalys Pharma has raised $105M across 1 round on record. The most recent is a Series B of $105M announced in Aug 2024.
When did Pathalys Pharma last raise funding?
Pathalys Pharma's most recent funding round on record is a Series B of $105M, announced in Aug 2024.
Who founded Pathalys Pharma?
FundedIQ lists Ashwin Ram (Founder) at Pathalys Pharma.
Where is Pathalys Pharma headquartered?
Pathalys Pharma is based in Raleigh, North Carolina, United States.
How many employees does Pathalys Pharma have?
Pathalys Pharma is in the 1-10 employee band.
How does Pathalys Pharma's funding compare to other Biotechnology startups?
Pathalys Pharma's latest round of $105M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Pathalys Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pathalys Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.